<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158689</url>
  </required_header>
  <id_info>
    <org_study_id>10017</org_study_id>
    <nct_id>NCT02158689</nct_id>
  </id_info>
  <brief_title>Comparison of Treatment Modalities in Poor Responders Undergoing IVF</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ercan Bastu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The accurate identification and efficient management of poor responders remains one of the
      most enigmatic challenges in assisted reproductive technology (ART). The investigators study
      will compare the letrozole/antagonist protocol to the hMG/antagonist protocol in women who
      poor responders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>The primary outcome measure will be the ongoing pregnancy rate (&gt;12 weeks' gestation) per started cycle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancellation Rate</measure>
    <time_frame>up to one month</time_frame>
    <description>One of the secondary outcome measures will be cancellation rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>up to one month</time_frame>
    <description>One of the secondary outcome measures will be number of oocytes retrieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transferable embryos</measure>
    <time_frame>up to one month</time_frame>
    <description>One of the secondary outcome measures will be number of transferable embryos.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>One of the secondary outcome measures will be implantation rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>One of the secondary outcome measures will be clinical pregnancy rates.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Poor Responders</condition>
  <arm_group>
    <arm_group_label>human menopausal gonadotropin (hMG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hMG at a dose of 300 IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day will be initiated on the second or third day of spontaneous menstruation and continued for 5 days. Again on the second or third day of spontaneous menstruation, 150 IU of hMG will be started until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of hCG as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human menopausal gonadotropin (hMG)</intervention_name>
    <arm_group_label>human menopausal gonadotropin (hMG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be considered eligible if they are poor ovarian responders according to
             the Bologna criteria (Ferraretti et al., 2011).

          -  Two out of three of the following criteria are essential in order to classify a
             patient as poor ovarian responder:

               -  advanced maternal age (≥40 years) or any other risk factor for poor ovarian
                  response;

               -  a poor ovarian response (≤3 oocytes with a conventional stimulation protocol); or

               -  an abnormal ovarian reserve test (antral follicle count, &lt;7 follicles or
                  anti-Mullerian hormone, &lt;1.1 ng/ml).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harika Yumru, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hasan F Buyru, M.D. Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ercan Bastu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Istanbul University School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Ercan Bastu</investigator_full_name>
    <investigator_title>Associate Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Poor responders</keyword>
  <keyword>letrozole</keyword>
  <keyword>human menopausal gonadotropin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

